Elanco Animal Health (ELAN) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY25 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Elanco Animal Health Reports Third Quarter 2025 Results
November 5, 2025 6:27 AM ESTRaising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target
Third Quarter 2025 Financial Results: Revenue of $1,137 million, an increase of 10% year-over-year; 9% organic constant currency growth Reported Net Loss of $34 million, Adjusted Net Income of $94 million Adjusted EBITDA of $198 million; Adjusted EBITDA Margin of 17.5%Â Reported EPS of $(0.07), Adjusted EPS of $0.19 Net leverage ratio of 3.7x Adjusted EBITDA Full Year 2025 Guidance: Raising revenue guidance to $4,645 million to $4,670 million; expect accelerating organic constant currency revenue growth of 6% to... More